Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

Trial: NivoRd, single-arm phase II (NCT02903381; Dana-Farber IRB 16-242). n = 8 patients with high-risk smoldering multiple myeloma treated with nivolumab + lenalidomide + dexamethasone. Patients identified by opaque codes (Pt01, Pt03-Pt09). Contents: per-cell imaging mass cytometry (IMC) AnnData; scRNA-seq AnnData for CD138-negative immune and CD138-positive plasma cells (NivoRd cells only); IMC phenotype tables (canonical 7-class lineages, Leiden clusters, 8 cellular neighborhoods); per-sample IMC summaries; LIANA differential ligand-receptor interactions; cytogenetic-vs-expression validation tables; MSigDB Hallmark 2020 GMT; per-patient response classifiers (DOR, COT, FAST, DOR_ordinal); README + data dictionary. License: CC BY 4.0. Code: https://github.com/ghobriallab/NivoRd_trial_2026